Jesus M Paramio
机构: Molecular Oncology Unit CIEMAT and Biomedical Res. Inst. Univ Hosp."12 de Octubre"
主页: ciemat.es
每年引用次数
引用次数
引用: 7,269
H-指数: 48
I10-指数 : 117
出版物: 239
Cancer Initiating Cells in Head and Neck Squamous Cell Carcinoma
Jesús M. Paramio
InTech
2011
Ectoderm-targeted overexpression of the glucocorticoid receptor induces hypohidrotic ectodermal dysplasia
Jose Luis Cascallana , Ana Bravo , Eva Donet , Hugo Leis
Endocrinology 146 ( 6) 2629 -2638
36
2005
Modulation of Cell Proliferation by Cytokeratins K10 and K16
Jesús M. Paramio , M. Llanos Casanova , Carmen Segrelles , Sybille Mittnacht
Molecular and Cellular Biology 19 ( 4) 3086 -3094
218
1999
p53 is phosphorylated at the carboxyl terminus and promotes the differentiation of human HaCaT keratinocytes
Jes�s M. Paramio , Carmen Segrelles , Sonia La�n , Elena G�mez-Casero
Molecular Carcinogenesis 29 ( 4) 251 -262
22
2000
Expression, localization, and activity of glycogen synthase kinase 3β during mouse skin tumorigenesis
Hugo Leis , Carmen Segrelles , Sergio Ruiz , Mirentxu Santos
Molecular Carcinogenesis 35 ( 4) 180 -185
62
2002
Functional link between retinoblastoma family of proteins and the Wnt signaling pathway in mouse epidermis.
Sergio Ruiz , Carmen Segrelles , Mirentxu Santos , M. Fernanda Lara
Developmental Dynamics 230 ( 3) 410 -418
21
2004
RB-independent activity of Cdk4/6 in bladder cancer.
Daniel E. Castellano , Carolina Rubio , Fernando López-Calderón , Cristina Segovia
Journal of Clinical Oncology 34
1
2016
Integrated analysis of mRNA and miRNA to unravel novel mechanisms of sunitinib long term response in mRCC.
Javier Puente , Nuria Lainez , Marta Dueñas , María José Méndez-Vidal
Journal of Clinical Oncology 34
2016
Inflammatory markers to predict prognosis in renal cell carcinoma (RCC) patients treated with immune checkpoint inhibitors (ICIs).
Lucia Carril , Alfonso Gomez De Liano Lista , Javier Pozas , Teresa Alonso Gordoa
Journal of Clinical Oncology 38 ( 6_suppl) 757 -757
2020
Atezolizumab + intravesical BCG (Bacillus Calmette-Guerin) in high-risk non-muscle invasive bladder cancer (NMIBC) patients: Institutional clinical and translational study (BladderGATE).
Daniel Castellano , Guillermo de Velasco , Maria Cruz Martin Soberón , Alberto Carretero-González
Journal of Clinical Oncology 38
1
2020
On the origin of epidermal cancers.
Corina Lorz , Carmen Segrelles , Jesus Paramio
Current Molecular Medicine 9 ( 3) 353 -364
8
2009
Regulating and replacing suppressor gene function with small synthetic molecules; design of an active synthetic suppressor protein
D.P. Lane , Ted Hupp , Emma Warbrick , Steve Picksley
Biochemical Society Transactions 24 ( 4)
1996
PIK3CA gene alterations in bladder cancer: Analysis of correlative series of transurethral resection (TUR)—Correlation with grade histology and tumor size.
Daniel E Castellano , Juan Sepulveda , Monica Martinez-Fernandez , Marta Dueñas Porto
Journal of Clinical Oncology 30 4584 -4584
2012
Association of immune gene expression profiling with vinflunine clinical benefit in metastatic urothelial cancer (mUC).
Guillermo de Velasco , Marta Dueñas , Alejandra Bernardini , Alvaro Pinto
Journal of Clinical Oncology 37
2019
Understanding Mouse Skin Carcinogenesis through Transgenic Approaches
Fernando Larcher , Angel Ramirez , M. Casanova , Manuel Navarro
Current Genomics 3 ( 4) 335 -353
2
2002
Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling
Agueda Buitrago-Perez , Guillermo Garaulet , Ana Vazquez-Carballo , Jesus Paramio
Current Genomics 10 ( 1) 26 -34
68
2009
A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.
Daniel E. Castellano , Miguel A. Climent , Ignacio Duran , Begona Mellado
Journal of Clinical Oncology 36
2018
BladderGATE: Atezolizumab+ intravesical BCG (bacillus Calmette-Guerin) upfront combination in patients with high risk non-muscle invasive bladder cancer (NMIBC)—Phase I-II ONCOSUR study.
Daniel Castellano , Guillermo de Velasco , Jorge Esteban Villarrubia , Marta Dueñas
Journal of Clinical Oncology 42 ( 4_suppl) 595 -595
1
2024
Atezolizumab+ intravesical BCG (bacillus Calmette-Guerin) upfront combination in high risk non–muscle-invasive bladder cancer (NMIBC) patients: Safety interim report of BladderGATE phase I-II study.
Daniel Castellano , Guillermo de Velasco , Alberto Carretero-González , Marta Dueñas
Journal of Clinical Oncology 41 ( 16_suppl) e16590 -e16590
1
2023
Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.
Daniel E Castellano , Ignacio Duran , Begona Mellado , Miguel Angel A Climent Duran
Journal of Clinical Oncology 40 ( 6_suppl) 490 -490
1
2022
Ramon Garcia-Escudero CRISTIAN SUAREZ CABRERA Jose Luis Rodriguez-Peralto FERNANDO LARCHER Francisco X Real Xosé R. Bustelo (ORCID:0000-0001-9398-6072) Manuel SERRANO David P Lane Stephan Beck Felipe Prosper EDUARDO PEREZ GOMEZ Rene Rodriguez CRISTINA SANCHEZ Julien Sage Nuria Lopez-Bigas Cristina Murga J. Silvio Gutkind, Ph.D. Erwin Knecht Mariano Barbacid